FDA Cuts Priority Review Voucher Fee By 32%; J&J In Line For Next Voucher?
This article was originally published in RPM Report
Executive Summary
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013. That may benefit J&J, assuming a pending tuberculosis agent is approved by FDA.